Your browser doesn't support javascript.
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.
Guebre-Xabier, Mimi; Patel, Nita; Tian, Jing-Hui; Zhou, Bin; Maciejewski, Sonia; Lam, Kristal; Portnoff, Alyse D; Massare, Michael J; Frieman, Matthew B; Piedra, Pedro A; Ellingsworth, Larry; Glenn, Gregory; Smith, Gale.
  • Guebre-Xabier M; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: mguebre-xabier@Novavax.com.
  • Patel N; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: npatel@novavax.com.
  • Tian JH; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: jhtian@Novavax.com.
  • Zhou B; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: bzhou@Novavax.com.
  • Maciejewski S; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: smaciejewski@Novavavax.com.
  • Lam K; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: klam@Novavax.com.
  • Portnoff AD; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: aportnoff@Novavax.com.
  • Massare MJ; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: mmassare@Novavax.com.
  • Frieman MB; University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA. Electronic address: mfrieman@som.umaryland.edu.
  • Piedra PA; Department of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine, Houston, TX, USA. Electronic address: ppiedra@bcm.edu.
  • Ellingsworth L; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: lellingsworth@novavax.com.
  • Glenn G; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: gglenn@Novavax.com.
  • Smith G; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: gsmith@Novavax.com.
Vaccine ; 38(50): 7892-7896, 2020 11 25.
Article in English | MEDLINE | ID: covidwho-899644
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective efficacy of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) produced from the full-length SARS-CoV-2 spike (S) glycoprotein stabilized in the prefusion conformation. Cynomolgus macaques (Macaca fascicularis) immunized with NVX-CoV2373 and the saponin-based Matrix-M™ adjuvant induced anti-S antibody that was neutralizing and blocked binding to the human angiotensin-converting enzyme 2 (hACE2) receptor. Following intranasal and intratracheal challenge with SARS-CoV-2, immunized macaques were protected against upper and lower infection and pulmonary disease. These results support ongoing phase 1/2 clinical studies of the safety and immunogenicity of NVX-CoV2327 vaccine (NCT04368988).
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Aged / Animals / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Vaccine Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Aged / Animals / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Vaccine Year: 2020 Document Type: Article